CLINICAL TRIALS PROFILE FOR SCOPOLAMINE

All Clinical Trials for SCOPOLAMINE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00006399 ↗	Effects of Estrogen on Memory in Post-Menopausal Women and Patients With Alzheimer's Disease	Completed	Alzheimer's Association	Phase 2	1999-09-01	The goal of this study is to examine whether the administration of estrogen to post-menopausal women and women with mild to moderate Alzheimer's disease will enhance their memory and their capacity for learning.
NCT00006399 ↗	Effects of Estrogen on Memory in Post-Menopausal Women and Patients With Alzheimer's Disease	Completed	Eisai Inc.	Phase 2	1999-09-01	The goal of this study is to examine whether the administration of estrogen to post-menopausal women and women with mild to moderate Alzheimer's disease will enhance their memory and their capacity for learning.
NCT00006399 ↗	Effects of Estrogen on Memory in Post-Menopausal Women and Patients With Alzheimer's Disease	Completed	Pfizer	Phase 2	1999-09-01	The goal of this study is to examine whether the administration of estrogen to post-menopausal women and women with mild to moderate Alzheimer's disease will enhance their memory and their capacity for learning.
NCT00006399 ↗	Effects of Estrogen on Memory in Post-Menopausal Women and Patients With Alzheimer's Disease	Completed	National Center for Research Resources (NCRR)	Phase 2	1999-09-01	The goal of this study is to examine whether the administration of estrogen to post-menopausal women and women with mild to moderate Alzheimer's disease will enhance their memory and their capacity for learning.
NCT00055575 ↗	Cholinergic Modulation of Condition and Emotion in Mood Disorders: Functional Neuroimaging Studies	Terminated	National Institute of Mental Health (NIMH)	Phase 2	2003-02-27	This study looks at the role of a specific brain chemical system in the mood and attention symptoms seen in major depression and bipolar disorders using functional brain imaging.
NCT00130026 ↗	Caffeine in the Prevention of Post-operative Nausea and Vomiting	Completed	Beth Israel Deaconess Medical Center	N/A	2005-03-01	The objective of this study is to determine if caffeine 500 mg intravenously is efficacious when added to standard anti-emetic prophylaxis in the prevention of post-operative nausea and vomiting (PONV) in patients undergoing ambulatory surgery under general anesthesia.
NCT00369915 ↗	The Antidepressant Efficacy of the Anticholinergic Scopolamine	Terminated	National Institute of Mental Health (NIMH)	Phase 2	2006-08-01	A previous study showed that the intravenous administration of scopolamine produces antidepressant effects. This study is designed to determine if other routes of administration of scopolamine produce antidepressant effects.

Clinical Trial Conditions for SCOPOLAMINE

Condition Name

Condition Name for SCOPOLAMINE
Intervention	Trials
Motion Sickness	12
Healthy	6
Postoperative Nausea and Vomiting	4
Nausea	4

Condition MeSH

Condition MeSH for SCOPOLAMINE
Intervention	Trials
Motion Sickness	15
Vomiting	12
Nausea	10
Depression	8

Clinical Trial Locations for SCOPOLAMINE

Trials by Country

Trials by Country for SCOPOLAMINE
Location	Trials
United States	57
China	5
Israel	4
France	4
United Kingdom	2

Trials by US State

Trials by US State for SCOPOLAMINE
Location	Trials
California	12
Texas	7
Connecticut	5
Maryland	4
Ohio	4

Clinical Trial Progress for SCOPOLAMINE

Clinical Trial Phase

Clinical Trial Phase for SCOPOLAMINE
Clinical Trial Phase	Trials
Phase 4	15
Phase 3	11
Phase 2/Phase 3	2

Clinical Trial Status

Clinical Trial Status for SCOPOLAMINE
Clinical Trial Phase	Trials
Completed	40
Recruiting	14
Unknown status	9

Clinical Trial Sponsors for SCOPOLAMINE

Sponsor Name

Sponsor Name for SCOPOLAMINE
Sponsor	Trials
Repurposed Therapeutics, Inc.	11
University of California, Los Angeles	3
Merck Sharp & Dohme Corp.	3

Sponsor Type

Sponsor Type for SCOPOLAMINE
Sponsor	Trials
Other	68
Industry	34
NIH	6